An interventional study of ZanEMR-AS and Audit and Feedback Benchmarking Dashboards in Acute Infectious Diseases, sponsored by Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland. Not yet recruiting at 1 site in Tanzania. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn if a digital decision support tool integrated within an electronic medical record system, with or without training and mentorship for health workers, can reduce unnecessary antibiotic prescribing in patients of all ages (children and adults) who visit primary healthcare clinics in Zanzibar, Tanzania with an acute infectious illness. The main question it aims to answer is:
Researchers will compare three groups of clinics to see if the approaches lead to fewer antibiotics being prescribed:
Participants will:
BACKGROUND
Antibiotic prescription is inappropriately high in outpatient primary care settings and are projected to increase over the next years (Sulis et al., 2020). Inappropriate antibiotic prescription is one of the biggest contributors to the development of antibiotic resistance at the individual and population level (Holmes et al., 2016). Consequently, bacterial antimicrobial resistance is directly responsible for 1.3 million deaths a year and rising, as much as malaria and HIV combined (Murray et al., 2022). The World Health Organization (WHO) has declared it as 'one of the biggest threats to global health, food security and development today'.
With over 80% of antibiotic prescription occurring at primary care, the need for antibiotic stewardship programs at the community level is especially important (Duffy et al., 2018).
Clinical decision support systems (CDSS) provide clinical guidance at the point of care, ranging from alerts within an electronic medical record (EMR) system, to comprehensive support throughout every step of the consultation process (often described as clinical decision support algorithms (CDSAs)) (Sutton et al., 2020). In some studies, CDSAs have led to a two to four-fold reduction in antibiotic prescription without increase in morbidity/mortality, while others have shown little to no reduction in antibiotic prescription (Ibrahim et al., 2026).
Despite their potential, many CDSAs have important limitations. Most existing tools focus on paediatric populations, many are not integrated within electronic medical record systems, leading to duplicate data entry, inefficient clinical workflows and poor uptake (Ibrahim et al., 2026).
In Zanzibar, the deployment of the national EMR system for primary healthcare facilities, called ZanEMR (Zanzibar Electronic Medical Record System), started in 2025, offers a unique opportunity to provide decision support to primary care clinicians.
While digital tools can support decision-making, sustained behavior change often requires the combination of multiple interventions including training, mentorship, and audit \& feedback (Arnold \& Straus, 2005; Mostofian et al., 2015).
OBJECTIVES
Primary objective:
To evaluate the effectiveness of two antibiotic stewardship interventions - both incorporating clinical decision support integrated into an electronic medical record system and one with an additional mentorship/training intervention - to reduce antibiotic prescribing for acute infectious illness in patients of all ages, compared to usual care at primary healthcare facilities.
Secondary objectives include:
Harm: To evaluate that there is no more harm to patients managed in intervention health facilities compared to patients in the control health facilities in terms of worse self-reported clinical status, and severe adverse outcome (hospitalization without referral or dead by day 7)
Feasibility and acceptability: The objective is to determine the feasibility and acceptability of the DAWA interventions by primary healthcare workers receiving the intervention and stakeholders involved in delivering the intervention, as well as determinants of rational antibiotic prescribing by primary healthcare workers exposed to the intervention.
Health Economics: The objective is to perform a cost and cost-effectiveness analysis on the impact of the interventions.
Comparative Effectiveness: The objective is to compare the two different interventions (Clinical decision support, 6 mentorship/training sessions with routine mentorship support vs clinical decision support and routine mentorship support) in terms of their impact on antibiotic prescribing and costs.
Other secondary objectives are to compare the intervention arms with control for the secondary outcomes stated outcome section.
STUDY DESIGN
Main study: DAWA I and II Cluster Randomized Controlled Trial
This three-arm, parallel-group, cluster randomized controlled trial (RCT) will evaluate the effectiveness of two intervention packages aimed at reducing antibiotic prescribing in primary care settings (superiority design), as described in the Arms and Intervention section.
During a first phase (DAWA I), interventions will be deployed as follows:
Intervention arm 1:
Intervention arm 2:
Control arm (Usual care):
- ZanEMR: Routinely used electronic medical record, as implemented by the MOHZ, without clinical decision support features for antibiotic stewardship
All study arms continue to use and receive:
During the second phase of the study (DAWA II), health care providers in arm 1 will stop attending Antibiotic Stewardship Club meetings, and both arm 1 and 2 will no longer receive visits supported by the study team. However, arm 1 and 2 will continue to access ZanEMR-AS and Audit and Feedback Dashboards. Routinely entered ZanEMR data will be collected to evaluate long term effectiveness of the different intervention packages.
ANCILLARY STUDIES
Feasibility and acceptability of the interventions by healthcare providers and stakeholders from the Ministry of Health: To assess the feasibility and acceptability of the interventions, semi-structured In-depth Interviews (IDIs) will be conducted with stakeholders from the Ministry of Health, and healthcare providers from facilities randomized to the intervention arms. Participants will be asked about their perception of the different intervention components, their utility, and potential challenges. In addition, we will conduct non-participant observations of antibiotic stewardship clubs, by systematically observing and documenting the discussions between healthcare providers during the monthly Antibiotic Stewardship Club meetings without directly engaging with or influencing the participants.
DAWA III - Before-After Analysis: If the DAWA I cluster RCT demonstrates that the antibiotic stewardship features embedded in ZanEMR (ZanEMR-AS) with or without Antibiotic Stewardship Club meetings shows promise in reducing antibiotic prescribing regardless of statistical significance, then ZanEMR-AS will be scaled across all health facilities using ZanEMR that were not already using ZanEMR-AS during the initial trial. A Before-After analysis will be conducted using routine ZanEMR data to assess changes in antibiotic prescribing behavior across the newly exposed facilities.
This analysis will help evaluate the real-world effectiveness of ZanEMR-AS, under conditions of routine clinical practice, and in a more diverse set of health facilities, located both in Unguja and Pemba islands.
Cost and cost-effectiveness study: The costs and cost-effectiveness of the two interventions strategies will be compared to usual care. This component of the study will help inform policy decisions on the scalability and value-for-money of the interventions.
628 studies on the registry are indexed under Communicable Diseases; 129 are open to participants now.
This study's planned enrollment of 5,850 is above the median of 89 across 381 interventional studies indexed under Communicable Diseases.
Browse Communicable Diseases studies →Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland is the lead sponsor of 23 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Eligibility criteria for participants:
Inclusion Criteria:
- Patients of all ages presenting to participating health facilities for a presumed acute infectious illness (presence of any of the following symptoms or signs for less than 2 weeks: fever, cough, runny nose, sore throat, ear pain, ear discharge, pain urinating, genital complaints, diarrhea, vomiting, skin infection [abscess, pustules]) for their initial consultation related to an acute infectious illness.
Exclusion Criteria:
Eligibility criteria for Health facilities:
Inclusion criteria:
Exclusion criteria:
- Health facilities that are planning to be closed for more than 2 weeks during the conduct of the study
Health facilities in this arm will receive the following interventions: * Digital Clinical Decision Support integrated within the Zanzibar Electronic Medical Record system (ZanEMR) called ZanEMR-AS (ZanEMR-Antibiotic Stewardship) with initial group training and supported mentorship visits * Audit and Feedback Benchmarking Dashboards * Monthly Antibiotic Stewardship Club Meetings (Months 0-5)
Other: ZanEMR-AS · Other: Audit and Feedback Benchmarking Dashboards · Other: Antibiotic Stewardship Club meetings
Health facilities in this arm will receive the following interventions: * Digital Clinical Decision Support integrated within ZanEMR (ZanEMR-AS) with initial group training and supported mentorship visits * Audit and Feedback Benchmarking Dashboards
Other: ZanEMR-AS · Other: Audit and Feedback Benchmarking Dashboards
Health facilities in this arm will pursue usual care, which includes: * ZanEMR: Routinely used electronic medical record, as implemented by the MOHZ, without clinical decision support features for antibiotic stewardship * Paper and pdf national guidelines including the Zanzibar Standard Treatment Guidelines, international guidelines including IMCI. * Routine supervision by district health management teams
ZanEMR-AS is a set of clinical decision support features to encourage antibiotic stewardship (AS), integrated within the Zanzibar Electronic Medical Record (ZanEMR) System developed by the Ministry of Health. At intervention start, a centralized group training will be conducted, to help healthcare workers understand and effectively use the new EMR features. Additionally, 1-2 visits per health facilities will be conducted to provide on-site mentorship. These visits will be conducted together with the respective District Health Management Teams (DHMTs) in Zanzibar, who conduct regular visits to primary health facilities as part of routine supervision.
Audit and feedback benchmarking dashboards will compare antibiotic prescription rates among health facilities and healthcare providers. Overall prescription rates, as well as prescription by WHO AWaRe categories, and by clinical syndromes will be presented. Dashboards will be shared with healthcare providers from participating health facilities and relevant public health officials including District Health Management Teams.
Antibiotic Stewardship Club meetings are monthly training and mentorship meetings with healthcare providers, conducted over a period of 6 months (6 meetings in total). The content of the meetings will include: 1. Review of antibiotic prescribing from the previous month and evolution over time during the club meetings of the participating health facilities utilizing the audit/feedback benchmarking dashboard. 2. Peer-to-peer discussions on challenges and opportunities of rational antibiotic prescribing 3. Targeted clinical training: Refresher training on specific syndromes, reviewing when an antibiotic is indicated or not. 4. Communication training on methods to explain why antibiotics are not necessary, with role play activities between healthcare providers
Systemic antibiotic prescription
Proportion of encounters with a systemic antibiotic prescribed at day 0 among patients enrolled in the study with a suspected infectious illness. This outcome is assessed during months 3 to 5 after the initiation of the interventions (Baseline month 0).
Time frame: At day 0 (day of initial encounter) (during months 3 to 5 after the initiation of the intervention)
Clinical status worse
Proportion of patient encounters for which patients report they are worse compared to baseline (day 0) consultation.
Time frame: At day 7 after enrollment (during months 3 to 5 after the initiation of the intervention)
Severe adverse outcome (composite outcome)
Proportion of patient encounters for which the patient is 1. Hospitalized without referral OR 2. Dead: Patients reported dead by day 7
Time frame: By day 7 after enrollment (during months 3 to 5 after the initiation of the intervention)
Unplanned follow-up consultation
Proportion of patient encounters for which a patient presents to a health facility for an unplanned follow-up consultation.
Time frame: By day 7 after enrollment (during months 3 to 5 after the initiation of the intervention)
Additional medications
Proportion of patient encounters for which the patient uses additional medications not prescribed by healthcare provider at the initial encounter.
Time frame: By day 7 after enrollment (during months 3 to 5 after the initiation of the intervention)
Diagnostic-concordant antibiotic prescribing
Proportion of patient encounters in which a systemic antibiotic was prescribed when clinically indicated based on the diagnosis, or not prescribed when not indicated\*(regardless of antibiotic class, dosage or administration route). \*Appropriate antibiotic prescription based on pre-specified matching of ICD-10 diagnoses requiring antibiotics based on national guidelines (and international guidelines if not clear in national guidelines)
Time frame: At day 0 (day of initial encounter) (during months 3 to 5 after the initiation of the intervention)
Antibiotics categorized as an "Access" antibiotic according to the WHO AWARE classification
Proportion of patient encounters prescribed an "Access" antibiotic according to the WHO AWARE classification (Access, Watch, Reserve, Not recommended) among all encounters prescribed a systemic antibiotic
Time frame: At day 0 (day of initial encounter) (during months 3 to 5 after the initiation of the intervention)
Long term systemic antibiotic prescription
Proportion of encounters presenting for an acute illness with a systemic antibiotic prescribed during months 6 to 11 after intervention initiation (after cessation of antibiotic stewardship club meetings and supported mentorship visits)
Time frame: At day 0 - day of initial encounter (during month 6 to 11)
Diagnostic-concordant systemic antibiotic prescribing (long term)
Proportion of patient encounters in which an antibiotic was prescribed when clinically indicated based on the diagnosis, or not prescribed when not indicated\* (regardless of antibiotic class, dosage or administration route). Assessed during months 6 to 11 after intervention initiation (after cessation of antibiotic stewardship club meetings and supported mentorship visits). \*Appropriate antibiotic prescription based on pre-specified matching of ICD-10 diagnoses requiring antibiotics based on national guidelines (and international guidelines if not clear in national guidelines)
Time frame: At day 0 - day of initial encounter (during month 6 to 11)
Antibiotics categorized as an "Access" antibiotic according to the WHO AWARE classification (long term)
Proportion of patient encounters prescribed an "Access" antibiotic according to the WHO AWARE classification (Access, Watch, Reserve, Not recommended) among all encounters prescribed a systemic antibiotic. Assessed during months 6 to 11 after intervention initiation (after cessation of antibiotic stewardship club meetings and supported mentorship visits).
Time frame: At day 0 - day of initial encounter (during month 6 to 11)
Trend in systemic antibiotic prescription over whole study period (exploratory)
Evolution over time of the proportion of encounters presenting for an acute illness with a systemic antibiotic prescribed. Assessed from month 0 to month 11.
Time frame: At day 0 - initial encounter (during month 0 to 11)
Systemic antibiotic prescription in all patients
Proportion of patient encounters prescribed a systemic antibiotic in all patients (not limited to those with a presumed infectious illness)
Time frame: At day 0 - initial encounter (during month 0-5)
Systemic antibiotic prescription in patients over the whole implementation period
Proportion of encounters prescribed a systemic antibiotic in patients with a presumed infectious illness, and during the whole implementation period (month 0-5)
Time frame: At day 0 - initial encounter (during month 0-5)
Know-do gap in terms of appropriate systemic antibiotic prescription in all patients in months 3-6
Proportion of encounters with or without appropriate systemic antibiotic prescription in comparison to knowledge on what is considered appropriate according to diagnosis\*. \*Appropriate antibiotic prescription based on pre-specified matching of ICD-10 diagnoses requiring antibiotics based on national guidelines (and international guidelines if not clear in national guidelines)
Time frame: At day 0 - initial encounter (during months 3 to 5 after the initiation of the intervention)
Plan to share: Yes — A de-identified version of the data will be made available upon request for research purposes only through a secure data repository. Because this study uses data from the national EMR, there remains a risk of re-identification, and complete anonymization is not possible. For this reason, the data cannot be made publicly available.
Supporting information: Study protocol, Statistical analysis plan
Time frame: The IPD and supporting information will be made available at the time of results publiation, with no end date.
Access criteria: Study protocol is made available publicly via Clinicaltrials.gov SAP will be made available publicly on the study website. IPD will be made available upon request through a secure data repository.
Start is estimated for Jan 2027; primary completion for Jul 2027, 6 months later.
Of 128 non-industry interventional studies with no phase under Communicable Diseases, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 36. This study's planned 6 months is below that.
Counting every sponsor, half of 144 studies reached it within 21 months; a quarter within 6 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland